Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients
Blood (2017)
  • Joanna Rhodes, University of Pennsylvania
  • Paul M. Barr, University of Rochester
  • Chaitra S. Ujjani, Georgetown University
  • Chadi Nabhan, Cardinal Health, Dublin, OH
  • Constantine S. Tam, Peter MacCallum Cancer Centre
  • Ryan Jacobs, Carolinas Healthcare System
  • Frederick Lansigan, Dartmouth–Hitchcock Medical Center
  • Brian T. Hill, Cleveland Clinic
  • Danielle M. Brander, Duke University
  • Mazyar Shadman, Fred Hutchinson Cancer Research Center
  • Alan P Skarbnik, John Theurer Cancer Center Hackensack Meridian Health, Hackensack, NJ
  • Jeffrey J. Pu, Pennsylvania State University
  • Alison R. Sehgal, University of Pittsburgh
  • John M. Pagel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
  • John N. Allan, Cornell University
  • Kaitlin Kennard, University of Pennsylvania
  • Bruce D. Cheson, Georgetown University Medical Center
  • Douglas F. Beach, Pennsylvania Hospital
  • Bhavisha Patel, MedStar Washington Hospital Center
  • Krista Isaac, Lankenau Medical Center
  • Hande H. Tuncer, Tufts Medical Center
  • Richard R. Furman, Cornell University
  • Anthony R. Mato, University of Pennsylvania
Link
Disciplines
Publication Date
December 7, 2017
Citation Information
Joanna Rhodes, Paul M. Barr, Chaitra S. Ujjani, Chadi Nabhan, et al.. "The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients" Blood Vol. 130 (2017) p. 4313 - 4313
Available at: http://works.bepress.com/john-pagel/308/